Stem definition | Drug id | CAS RN |
---|---|---|
opioid receptor antagonists/agonists related to normorphine | 1765 | 16590-41-3 |
Dose | Unit | Route |
---|---|---|
50 | mg | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 100 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 1 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.44 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 22 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 7.60 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 57 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.79 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 1.90 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Nov. 20, 1984 | FDA | TEVA WOMENS |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Injection site reaction | 3314.27 | 19.26 | 1126 | 22638 | 50040 | 53275262 |
Alcoholism | 2573.05 | 19.26 | 493 | 23271 | 1738 | 53323564 |
Injection site mass | 2473.19 | 19.26 | 690 | 23074 | 15524 | 53309778 |
Injection site pain | 1239.75 | 19.26 | 715 | 23049 | 112676 | 53212626 |
Injection site induration | 916.68 | 19.26 | 278 | 23486 | 8380 | 53316922 |
Drug dependence | 537.65 | 19.26 | 238 | 23526 | 21234 | 53304068 |
Therapeutic response shortened | 445.42 | 19.26 | 153 | 23611 | 6886 | 53318416 |
Feeling abnormal | 361.91 | 19.26 | 369 | 23395 | 134932 | 53190370 |
Product administered at inappropriate site | 280.75 | 19.26 | 85 | 23679 | 2537 | 53322765 |
Withdrawal syndrome | 254.01 | 19.26 | 138 | 23626 | 19163 | 53306139 |
Injection site swelling | 222.11 | 19.26 | 170 | 23594 | 42458 | 53282844 |
Injection site abscess | 201.41 | 19.26 | 54 | 23710 | 1027 | 53324275 |
Inappropriate schedule of product administration | 195.78 | 19.26 | 202 | 23562 | 74676 | 53250626 |
Nausea | 179.59 | 19.26 | 736 | 23028 | 755355 | 52569947 |
Anxiety | 138.41 | 19.26 | 284 | 23480 | 196420 | 53128882 |
Inadequate analgesia | 137.90 | 19.26 | 51 | 23713 | 2844 | 53322458 |
Drug use disorder | 136.21 | 19.26 | 52 | 23712 | 3167 | 53322135 |
Insomnia | 129.12 | 19.26 | 268 | 23496 | 186804 | 53138498 |
Injection site warmth | 127.27 | 19.26 | 79 | 23685 | 14049 | 53311253 |
Product dose omission issue | 123.55 | 19.26 | 267 | 23497 | 191353 | 53133949 |
Needle issue | 120.52 | 19.26 | 60 | 23704 | 6952 | 53318350 |
Alcohol use | 115.77 | 19.26 | 41 | 23723 | 2017 | 53323285 |
Drug screen positive | 113.42 | 19.26 | 48 | 23716 | 3824 | 53321478 |
Injection site nodule | 111.84 | 19.26 | 46 | 23718 | 3411 | 53321891 |
Lack of injection site rotation | 95.94 | 19.26 | 23 | 23741 | 272 | 53325030 |
Substance abuse | 94.01 | 19.26 | 44 | 23720 | 4450 | 53320852 |
Tremor | 88.83 | 19.26 | 182 | 23582 | 125554 | 53199748 |
Alcohol poisoning | 85.62 | 19.26 | 32 | 23732 | 1837 | 53323465 |
Headache | 85.14 | 19.26 | 466 | 23298 | 536355 | 52788947 |
Rheumatoid arthritis | 83.45 | 19.26 | 19 | 23745 | 314512 | 53010790 |
Product administration error | 80.80 | 19.26 | 71 | 23693 | 21460 | 53303842 |
Depression | 80.30 | 19.26 | 220 | 23544 | 182832 | 53142470 |
Body tinea | 79.43 | 19.26 | 27 | 23737 | 1174 | 53324128 |
Lack of administration site rotation | 77.93 | 19.26 | 12 | 23752 | 3 | 53325299 |
Pneumonia | 76.88 | 19.26 | 43 | 23721 | 407126 | 52918176 |
Injection site pruritus | 74.08 | 19.26 | 92 | 23672 | 41497 | 53283805 |
Euphoric mood | 72.68 | 19.26 | 37 | 23727 | 4492 | 53320810 |
Acute kidney injury | 72.17 | 19.26 | 13 | 23751 | 253855 | 53071447 |
Injection site erythema | 70.83 | 19.26 | 125 | 23639 | 77124 | 53248178 |
Inhibitory drug interaction | 69.11 | 19.26 | 29 | 23735 | 2261 | 53323041 |
Injection site discomfort | 66.66 | 19.26 | 33 | 23731 | 3775 | 53321527 |
Dependence | 64.24 | 19.26 | 27 | 23737 | 2114 | 53323188 |
Dizziness | 64.19 | 19.26 | 331 | 23433 | 371928 | 52953374 |
Anaemia | 63.57 | 19.26 | 22 | 23742 | 276696 | 53048606 |
Injection site cellulitis | 63.28 | 19.26 | 23 | 23741 | 1220 | 53324082 |
Injection site cyst | 62.36 | 19.26 | 12 | 23752 | 43 | 53325259 |
Drug titration error | 60.42 | 19.26 | 19 | 23745 | 644 | 53324658 |
Infection susceptibility increased | 59.83 | 19.26 | 27 | 23737 | 2510 | 53322792 |
Necrosis ischaemic | 59.52 | 19.26 | 20 | 23744 | 839 | 53324463 |
Irritability | 57.58 | 19.26 | 70 | 23694 | 30883 | 53294419 |
Injection site infection | 52.73 | 19.26 | 22 | 23742 | 1691 | 53323611 |
Alcohol abuse | 51.98 | 19.26 | 23 | 23741 | 2041 | 53323261 |
Feeling drunk | 50.61 | 19.26 | 28 | 23736 | 4021 | 53321281 |
Hypotension | 50.59 | 19.26 | 25 | 23739 | 254051 | 53071251 |
Imprisonment | 49.90 | 19.26 | 13 | 23751 | 220 | 53325082 |
Impaired work ability | 47.99 | 19.26 | 44 | 23720 | 14046 | 53311256 |
Food craving | 47.73 | 19.26 | 20 | 23744 | 1554 | 53323748 |
Poor quality sleep | 47.49 | 19.26 | 48 | 23716 | 17275 | 53308027 |
Dyspnoea | 46.70 | 19.26 | 122 | 23642 | 586110 | 52739192 |
Glucose tolerance impaired | 46.02 | 19.26 | 29 | 23735 | 5291 | 53320011 |
Pneumonia streptococcal | 45.54 | 19.26 | 20 | 23744 | 1743 | 53323559 |
Neutropenia | 45.54 | 19.26 | 8 | 23756 | 159177 | 53166125 |
Injection site bruising | 45.43 | 19.26 | 69 | 23695 | 37577 | 53287725 |
Hospitalisation | 44.54 | 19.26 | 98 | 23666 | 70914 | 53254388 |
Thrombocytopenia | 44.29 | 19.26 | 5 | 23759 | 138722 | 53186580 |
Magnesium deficiency | 43.79 | 19.26 | 14 | 23750 | 501 | 53324801 |
Feeling jittery | 43.64 | 19.26 | 39 | 23725 | 12044 | 53313258 |
Impaired quality of life | 43.26 | 19.26 | 27 | 23737 | 4844 | 53320458 |
General physical health deterioration | 42.88 | 19.26 | 7 | 23757 | 146935 | 53178367 |
Beta haemolytic streptococcal infection | 42.87 | 19.26 | 20 | 23744 | 2007 | 53323295 |
Drug intolerance | 42.77 | 19.26 | 19 | 23745 | 205474 | 53119828 |
Systemic lupus erythematosus | 41.38 | 19.26 | 4 | 23760 | 125410 | 53199892 |
Pregnancy | 41.35 | 19.26 | 60 | 23704 | 31381 | 53293921 |
Crying | 40.84 | 19.26 | 50 | 23714 | 22212 | 53303090 |
Alcohol withdrawal syndrome | 40.80 | 19.26 | 15 | 23749 | 822 | 53324480 |
Panic attack | 40.75 | 19.26 | 49 | 23715 | 21369 | 53303933 |
Surgery | 40.59 | 19.26 | 60 | 23704 | 31904 | 53293398 |
Treatment failure | 40.07 | 19.26 | 5 | 23759 | 128398 | 53196904 |
Injection site necrosis | 39.99 | 19.26 | 17 | 23747 | 1369 | 53323933 |
Pyrexia | 39.34 | 19.26 | 75 | 23689 | 403118 | 52922184 |
Illness | 39.00 | 19.26 | 49 | 23715 | 22347 | 53302955 |
Wrong technique in product usage process | 38.96 | 19.26 | 84 | 23680 | 59948 | 53265354 |
Suicidal ideation | 37.37 | 19.26 | 83 | 23681 | 60428 | 53264874 |
Haemoglobin decreased | 36.95 | 19.26 | 8 | 23756 | 137299 | 53188003 |
Platelet count decreased | 36.87 | 19.26 | 3 | 23761 | 108096 | 53217206 |
Condition aggravated | 36.85 | 19.26 | 47 | 23717 | 297087 | 53028215 |
Malabsorption from injection site | 36.84 | 19.26 | 7 | 23757 | 23 | 53325279 |
Oedema peripheral | 36.80 | 19.26 | 15 | 23749 | 170772 | 53154530 |
Somnolence | 36.71 | 19.26 | 160 | 23604 | 167574 | 53157728 |
Apathy | 36.48 | 19.26 | 30 | 23734 | 8282 | 53317020 |
Malaise | 35.28 | 19.26 | 276 | 23488 | 357341 | 52967961 |
Detoxification | 34.81 | 19.26 | 6 | 23758 | 9 | 53325293 |
Drug withdrawal syndrome | 33.30 | 19.26 | 51 | 23713 | 27971 | 53297331 |
Atrial fibrillation | 33.29 | 19.26 | 5 | 23759 | 111647 | 53213655 |
Infusion related reaction | 33.11 | 19.26 | 14 | 23750 | 155943 | 53169359 |
Sepsis | 32.97 | 19.26 | 12 | 23752 | 146417 | 53178885 |
Cough | 32.51 | 19.26 | 40 | 23724 | 256853 | 53068449 |
Toothache | 32.48 | 19.26 | 40 | 23724 | 17874 | 53307428 |
Fatigue | 32.11 | 19.26 | 479 | 23285 | 730027 | 52595275 |
Abnormal dreams | 32.07 | 19.26 | 31 | 23733 | 10570 | 53314732 |
Cold sweat | 31.39 | 19.26 | 32 | 23732 | 11630 | 53313672 |
Feeling of despair | 30.77 | 19.26 | 16 | 23748 | 2029 | 53323273 |
Death | 30.19 | 19.26 | 72 | 23692 | 357160 | 52968142 |
Mood altered | 30.11 | 19.26 | 34 | 23730 | 13867 | 53311435 |
Disease progression | 29.40 | 19.26 | 5 | 23759 | 101915 | 53223387 |
Restless legs syndrome | 28.90 | 19.26 | 37 | 23727 | 17186 | 53308116 |
Cardiac arrest | 28.37 | 19.26 | 4 | 23760 | 93663 | 53231639 |
White blood cell count decreased | 28.36 | 19.26 | 10 | 23754 | 124465 | 53200837 |
Pulmonary embolism | 28.20 | 19.26 | 8 | 23756 | 114434 | 53210868 |
Restlessness | 27.74 | 19.26 | 47 | 23717 | 28040 | 53297262 |
Hypersomnia | 27.23 | 19.26 | 35 | 23729 | 16320 | 53308982 |
Aspartate aminotransferase increased | 26.88 | 19.26 | 3 | 23761 | 84026 | 53241276 |
Caffeine consumption | 26.87 | 19.26 | 4 | 23760 | 0 | 53325302 |
Exposure during pregnancy | 26.83 | 19.26 | 11 | 23753 | 124849 | 53200453 |
Alanine aminotransferase increased | 26.71 | 19.26 | 5 | 23759 | 95090 | 53230212 |
Fall | 26.66 | 19.26 | 77 | 23687 | 358363 | 52966939 |
Nervousness | 26.56 | 19.26 | 48 | 23716 | 30130 | 53295172 |
Death of relative | 26.28 | 19.26 | 8 | 23756 | 243 | 53325059 |
Renal failure | 26.17 | 19.26 | 10 | 23754 | 118442 | 53206860 |
Migraine | 26.08 | 19.26 | 87 | 23677 | 80330 | 53244972 |
Product use issue | 25.90 | 19.26 | 15 | 23749 | 139569 | 53185733 |
Mass | 25.78 | 19.26 | 30 | 23734 | 12639 | 53312663 |
Drug screen false positive | 25.68 | 19.26 | 11 | 23753 | 902 | 53324400 |
Hyperammonaemia | 25.61 | 19.26 | 20 | 23744 | 5129 | 53320173 |
Bone density decreased | 25.58 | 19.26 | 28 | 23736 | 11036 | 53314266 |
Adiposis dolorosa | 25.47 | 19.26 | 8 | 23756 | 270 | 53325032 |
Anger | 24.64 | 19.26 | 29 | 23735 | 12361 | 53312941 |
Purpura | 24.29 | 19.26 | 27 | 23737 | 10826 | 53314476 |
Hyponatraemia | 24.28 | 19.26 | 9 | 23755 | 108598 | 53216704 |
Road traffic accident | 24.14 | 19.26 | 42 | 23722 | 25589 | 53299713 |
Blood creatinine increased | 23.97 | 19.26 | 4 | 23760 | 82658 | 53242644 |
Arthropathy | 23.78 | 19.26 | 17 | 23747 | 141436 | 53183866 |
Injection site irritation | 23.62 | 19.26 | 18 | 23746 | 4454 | 53320848 |
Oral herpes | 23.01 | 19.26 | 37 | 23727 | 21142 | 53304160 |
Rash | 22.67 | 19.26 | 112 | 23652 | 446079 | 52879223 |
Dental operation | 22.34 | 19.26 | 11 | 23753 | 1243 | 53324059 |
Urinary tract infection | 22.17 | 19.26 | 46 | 23718 | 239857 | 53085445 |
Depressed mood | 22.03 | 19.26 | 50 | 23714 | 36914 | 53288388 |
Snoring | 21.67 | 19.26 | 16 | 23748 | 3776 | 53321526 |
Hyperhidrosis | 21.66 | 19.26 | 93 | 23671 | 96700 | 53228602 |
Wound | 21.47 | 19.26 | 7 | 23757 | 91550 | 53233752 |
Product preparation error | 21.44 | 19.26 | 17 | 23747 | 4458 | 53320844 |
Yawning | 21.18 | 19.26 | 10 | 23754 | 1031 | 53324271 |
Intentional overdose | 21.16 | 19.26 | 72 | 23692 | 67133 | 53258169 |
Gastrointestinal haemorrhage | 20.96 | 19.26 | 5 | 23759 | 80325 | 53244977 |
Renal impairment | 20.20 | 19.26 | 6 | 23758 | 83312 | 53241990 |
Injection site haematoma | 20.19 | 19.26 | 19 | 23745 | 6266 | 53319036 |
Decreased appetite | 20.10 | 19.26 | 164 | 23600 | 214810 | 53110492 |
Joint swelling | 20.03 | 19.26 | 47 | 23717 | 234591 | 53090711 |
Product preparation issue | 19.99 | 19.26 | 8 | 23756 | 552 | 53324750 |
Patient dissatisfaction with treatment | 19.95 | 19.26 | 5 | 23759 | 72 | 53325230 |
Disturbance in attention | 19.93 | 19.26 | 46 | 23718 | 34337 | 53290965 |
Diaphragmatic paralysis | 19.70 | 19.26 | 8 | 23756 | 574 | 53324728 |
Coronavirus infection | 19.65 | 19.26 | 14 | 23750 | 3126 | 53322176 |
Mood swings | 19.62 | 19.26 | 31 | 23733 | 17455 | 53307847 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Injection site reaction | 5057.27 | 27.73 | 1226 | 19997 | 10343 | 32481960 |
Alcoholism | 2903.55 | 27.73 | 629 | 20594 | 2943 | 32489360 |
Injection site pain | 2768.40 | 27.73 | 971 | 20252 | 32087 | 32460216 |
Injection site mass | 1398.44 | 27.73 | 380 | 20843 | 5121 | 32487182 |
Drug dependence | 923.53 | 27.73 | 400 | 20823 | 23084 | 32469219 |
Feeling abnormal | 652.40 | 27.73 | 435 | 20788 | 59988 | 32432315 |
Therapeutic response shortened | 609.46 | 27.73 | 193 | 21030 | 4527 | 32487776 |
Injection site induration | 587.34 | 27.73 | 165 | 21058 | 2519 | 32489784 |
Product administered at inappropriate site | 395.38 | 27.73 | 111 | 21112 | 1688 | 32490615 |
Injection site swelling | 371.99 | 27.73 | 162 | 21061 | 9422 | 32482881 |
Withdrawal syndrome | 350.78 | 27.73 | 167 | 21056 | 11955 | 32480348 |
Needle issue | 312.28 | 27.73 | 115 | 21108 | 4294 | 32488009 |
Product dose omission issue | 309.47 | 27.73 | 357 | 20866 | 102218 | 32390085 |
Insomnia | 264.28 | 27.73 | 326 | 20897 | 100022 | 32392281 |
Drug use disorder | 251.09 | 27.73 | 93 | 21130 | 3528 | 32488775 |
Alcohol use | 195.27 | 27.73 | 76 | 21147 | 3307 | 32488996 |
Inappropriate schedule of product administration | 193.64 | 27.73 | 191 | 21032 | 45634 | 32446669 |
Injection site discomfort | 193.28 | 27.73 | 59 | 21164 | 1217 | 32491086 |
Lack of injection site rotation | 191.88 | 27.73 | 37 | 21186 | 80 | 32492223 |
Depression | 160.13 | 27.73 | 252 | 20971 | 96808 | 32395495 |
Pain | 159.76 | 27.73 | 367 | 20856 | 187189 | 32305114 |
Drug screen positive | 155.77 | 27.73 | 69 | 21154 | 4172 | 32488131 |
Acute kidney injury | 141.68 | 27.73 | 14 | 21209 | 293454 | 32198849 |
Anxiety | 136.33 | 27.73 | 233 | 20990 | 95772 | 32396531 |
Substance abuse | 119.31 | 27.73 | 68 | 21155 | 7039 | 32485264 |
Product administration error | 116.33 | 27.73 | 90 | 21133 | 15535 | 32476768 |
Headache | 114.28 | 27.73 | 333 | 20890 | 195864 | 32296439 |
Alcohol poisoning | 112.76 | 27.73 | 51 | 21172 | 3238 | 32489065 |
Nausea | 112.08 | 27.73 | 459 | 20764 | 320390 | 32171913 |
Injection site abscess | 110.03 | 27.73 | 34 | 21189 | 731 | 32491572 |
Euphoric mood | 109.81 | 27.73 | 58 | 21165 | 5169 | 32487134 |
Malaise | 107.31 | 27.73 | 305 | 20918 | 176833 | 32315470 |
Pneumonia | 101.42 | 27.73 | 53 | 21170 | 355199 | 32137104 |
Dependence | 101.09 | 27.73 | 36 | 21187 | 1217 | 32491086 |
Imprisonment | 100.73 | 27.73 | 29 | 21194 | 484 | 32491819 |
Drug withdrawal syndrome | 99.94 | 27.73 | 92 | 21131 | 20139 | 32472164 |
Anaemia | 99.56 | 27.73 | 14 | 21209 | 223610 | 32268693 |
Apathy | 91.11 | 27.73 | 56 | 21167 | 6659 | 32485644 |
Irritability | 89.91 | 27.73 | 95 | 21128 | 24559 | 32467744 |
Inadequate analgesia | 81.39 | 27.73 | 39 | 21184 | 2824 | 32489479 |
Feeling drunk | 79.79 | 27.73 | 34 | 21189 | 1869 | 32490434 |
Yawning | 75.65 | 27.73 | 24 | 21199 | 564 | 32491739 |
Injection site erythema | 74.96 | 27.73 | 68 | 21155 | 14600 | 32477703 |
Injection site bruising | 73.86 | 27.73 | 52 | 21171 | 7768 | 32484535 |
Injection site nerve damage | 70.51 | 27.73 | 12 | 21211 | 7 | 32492296 |
Lack of administration site rotation | 67.04 | 27.73 | 11 | 21212 | 3 | 32492300 |
Injection site warmth | 66.52 | 27.73 | 30 | 21193 | 1891 | 32490412 |
Decreased appetite | 64.71 | 27.73 | 241 | 20982 | 160572 | 32331731 |
Road traffic accident | 61.63 | 27.73 | 66 | 21157 | 17315 | 32474988 |
Renal failure | 60.77 | 27.73 | 8 | 21215 | 134470 | 32357833 |
Tremor | 60.22 | 27.73 | 151 | 21072 | 81126 | 32411177 |
Injection site nodule | 59.39 | 27.73 | 26 | 21197 | 1527 | 32490776 |
Emotional poverty | 59.28 | 27.73 | 19 | 21204 | 462 | 32491841 |
Fatigue | 58.06 | 27.73 | 409 | 20814 | 350292 | 32142011 |
Sepsis | 57.96 | 27.73 | 16 | 21207 | 158818 | 32333485 |
Toxicity to various agents | 57.81 | 27.73 | 22 | 21201 | 178019 | 32314284 |
Hypotension | 57.55 | 27.73 | 35 | 21188 | 216075 | 32276228 |
Thrombocytopenia | 55.89 | 27.73 | 14 | 21209 | 148285 | 32344018 |
Feeling of despair | 55.63 | 27.73 | 22 | 21201 | 998 | 32491305 |
Dyspnoea | 55.22 | 27.73 | 95 | 21128 | 361950 | 32130353 |
Atrial fibrillation | 55.05 | 27.73 | 6 | 21217 | 116698 | 32375605 |
Alcohol withdrawal syndrome | 53.91 | 27.73 | 24 | 21199 | 1467 | 32490836 |
Pyrexia | 53.45 | 27.73 | 79 | 21144 | 319889 | 32172414 |
Depressed mood | 52.11 | 27.73 | 62 | 21161 | 18238 | 32474065 |
Platelet count decreased | 51.33 | 27.73 | 7 | 21216 | 114584 | 32377719 |
Neutropenia | 50.61 | 27.73 | 15 | 21208 | 142160 | 32350143 |
Haemoglobin decreased | 49.78 | 27.73 | 9 | 21214 | 119662 | 32372641 |
Respiratory failure | 46.94 | 27.73 | 7 | 21216 | 107175 | 32385128 |
Condition aggravated | 46.10 | 27.73 | 22 | 21201 | 155639 | 32336664 |
Anger | 45.40 | 27.73 | 47 | 21176 | 11857 | 32480446 |
Injection site pruritus | 45.13 | 27.73 | 35 | 21188 | 6055 | 32486248 |
Disease progression | 44.95 | 27.73 | 3 | 21220 | 86859 | 32405444 |
Pancytopenia | 44.82 | 27.73 | 4 | 21219 | 91231 | 32401072 |
Mood altered | 43.00 | 27.73 | 40 | 21183 | 8864 | 32483439 |
Blood creatinine increased | 42.74 | 27.73 | 6 | 21217 | 96126 | 32396177 |
Oedema peripheral | 42.53 | 27.73 | 11 | 21212 | 114080 | 32378223 |
Injection site cellulitis | 42.09 | 27.73 | 15 | 21208 | 508 | 32491795 |
Gait disturbance | 41.45 | 27.73 | 131 | 21092 | 80277 | 32412026 |
Restlessness | 41.44 | 27.73 | 65 | 21158 | 24816 | 32467487 |
Substance use disorder | 41.15 | 27.73 | 12 | 21211 | 210 | 32492093 |
Cardiac failure congestive | 40.94 | 27.73 | 4 | 21219 | 84848 | 32407455 |
Hospitalisation | 40.54 | 27.73 | 95 | 21128 | 48876 | 32443427 |
Overdose | 40.52 | 27.73 | 137 | 21086 | 86940 | 32405363 |
Toothache | 40.31 | 27.73 | 33 | 21190 | 6168 | 32486135 |
Cardiac failure | 40.11 | 27.73 | 6 | 21217 | 91667 | 32400636 |
Hypersomnia | 39.92 | 27.73 | 44 | 21179 | 11917 | 32480386 |
General physical health deterioration | 39.50 | 27.73 | 13 | 21210 | 115246 | 32377057 |
Alcohol abuse | 38.24 | 27.73 | 28 | 21195 | 4444 | 32487859 |
Substance use | 37.78 | 27.73 | 14 | 21209 | 531 | 32491772 |
Hangover | 37.54 | 27.73 | 17 | 21206 | 1082 | 32491221 |
Injection site inflammation | 37.08 | 27.73 | 15 | 21208 | 722 | 32491581 |
Abdominal pain upper | 36.82 | 27.73 | 112 | 21111 | 67226 | 32425077 |
Coronavirus infection | 35.78 | 27.73 | 25 | 21198 | 3687 | 32488616 |
White blood cell count decreased | 35.54 | 27.73 | 8 | 21215 | 91190 | 32401113 |
Myocardial infarction | 35.34 | 27.73 | 19 | 21204 | 125657 | 32366646 |
Sciatic nerve injury | 35.05 | 27.73 | 9 | 21214 | 95 | 32492208 |
Death of relative | 34.91 | 27.73 | 7 | 21216 | 20 | 32492283 |
Wrong technique in product usage process | 34.62 | 27.73 | 73 | 21150 | 34986 | 32457317 |
Mood swings | 34.35 | 27.73 | 34 | 21189 | 8131 | 32484172 |
Product preparation error | 34.20 | 27.73 | 19 | 21204 | 1871 | 32490432 |
Panic attack | 32.53 | 27.73 | 35 | 21188 | 9226 | 32483077 |
Energy increased | 31.44 | 27.73 | 16 | 21207 | 1319 | 32490984 |
Hyperhidrosis | 31.37 | 27.73 | 110 | 21113 | 71058 | 32421245 |
Urinary tract infection | 31.24 | 27.73 | 7 | 21216 | 80064 | 32412239 |
Thinking abnormal | 30.51 | 27.73 | 27 | 21196 | 5608 | 32486695 |
Injection site infection | 30.50 | 27.73 | 14 | 21209 | 919 | 32491384 |
Libido decreased | 30.44 | 27.73 | 25 | 21198 | 4693 | 32487610 |
Muscle spasms | 30.32 | 27.73 | 108 | 21115 | 70310 | 32421993 |
Feeling jittery | 29.67 | 27.73 | 23 | 21200 | 3976 | 32488327 |
Product use in unapproved indication | 29.58 | 27.73 | 10 | 21213 | 87194 | 32405109 |
Emotional disorder | 29.32 | 27.73 | 26 | 21197 | 5415 | 32486888 |
Mobility decreased | 29.04 | 27.73 | 60 | 21163 | 28349 | 32463954 |
Chromaturia | 28.64 | 27.73 | 41 | 21182 | 14437 | 32477866 |
Bradycardia | 28.44 | 27.73 | 6 | 21217 | 71556 | 32420747 |
Suicidal ideation | 28.42 | 27.73 | 71 | 21152 | 38012 | 32454291 |
Surgery | 28.41 | 27.73 | 38 | 21185 | 12561 | 32479742 |
Migraine | 28.25 | 27.73 | 40 | 21183 | 13945 | 32478358 |
Drug interaction | 28.18 | 27.73 | 63 | 21160 | 218122 | 32274181 |
Alcoholic hangover | 27.74 | 27.73 | 5 | 21218 | 6 | 32492297 |
Source | Code | Description |
---|---|---|
ATC | A08AA62 | ALIMENTARY TRACT AND METABOLISM ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS Centrally acting antiobesity products |
ATC | N02AA56 | NERVOUS SYSTEM ANALGESICS OPIOIDS Natural opium alkaloids |
ATC | N07BB04 | NERVOUS SYSTEM OTHER NERVOUS SYSTEM DRUGS DRUGS USED IN ADDICTIVE DISORDERS Drugs used in alcohol dependence |
FDA MoA | N0000000154 | Opioid Antagonists |
MeSH PA | D000427 | Alcohol Deterrents |
MeSH PA | D002491 | Central Nervous System Agents |
MeSH PA | D009292 | Narcotic Antagonists |
MeSH PA | D018373 | Peripheral Nervous System Agents |
MeSH PA | D018689 | Sensory System Agents |
CHEBI has role | CHEBI:35488 | CNS depressants |
CHEBI has role | CHEBI:35703 | Xenobiotic |
CHEBI has role | CHEBI:50137 | mu-opioid receptor antagonists |
CHEBI has role | CHEBI:78298 | environmental contaminants |
CHEBI has role | CHEBI:90755 | antidote to opioid overdose |
FDA EPC | N0000175691 | Opioid Antagonist |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Alcoholism | indication | 7200002 | |
Severe pain | indication | 76948002 | |
Chronic pain | indication | 82423001 | |
Obesity | indication | 414916001 | DOID:9970 |
Prevention of opioid abuse | indication | 426928008 | |
Therapeutic opioid induced constipation | indication | 136801000119102 | |
Severe Pain with Opioid Tolerance | indication | ||
Chronic Pain with Opioid Tolerance | indication | ||
Neuropathic pain | off-label use | 247398009 | |
Suicidal thoughts | contraindication | 6471006 | |
Alcohol withdrawal delirium | contraindication | 8635005 | |
Chronic obstructive lung disease | contraindication | 13645005 | DOID:3083 |
Chronic disease of respiratory system | contraindication | 17097001 | |
Alcohol intoxication | contraindication | 25702006 | |
Shock | contraindication | 27942005 | |
Hypercapnia | contraindication | 29596007 | |
Depressive disorder | contraindication | 35489007 | |
Acute hepatitis | contraindication | 37871000 | |
Disorder of gallbladder | contraindication | 39621005 | DOID:0060262 |
Gastrointestinal ulcer | contraindication | 40845000 | |
Hypothyroidism | contraindication | 40930008 | DOID:1459 |
Low blood pressure | contraindication | 45007003 | |
Gastrointestinal perforation | contraindication | 51875005 | |
Paralytic ileus | contraindication | 55525008 | DOID:8442 |
Acute nephropathy | contraindication | 58574008 | |
Hepatic failure | contraindication | 59927004 | |
Substance abuse | contraindication | 66214007 | |
Benign intracranial hypertension | contraindication | 68267002 | DOID:11459 |
Opioid dependence | contraindication | 75544000 | DOID:2559 |
Urethral stricture | contraindication | 76618002 | |
Decreased respiratory function | contraindication | 80954004 | |
Injury of head | contraindication | 82271004 | |
Cor pulmonale | contraindication | 83291003 | DOID:8515 |
Opioid withdrawal | contraindication | 87132004 | |
Disorder of biliary tract | contraindication | 105997008 | DOID:9741 |
Gastrointestinal obstruction | contraindication | 126765001 | |
Seizure disorder | contraindication | 128613002 | |
Drug-induced psychosis | contraindication | 191483003 | DOID:1742 |
Acute hepatic failure | contraindication | 197270009 | |
Acute pancreatitis | contraindication | 197456007 | DOID:2913 |
Impaired renal function disorder | contraindication | 197663003 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Chronic diarrhea | contraindication | 236071009 | |
Benign prostatic hyperplasia | contraindication | 266569009 | |
Primary malignant neoplasm of gastrointestinal tract | contraindication | 363745004 | |
Macrocolon | contraindication | 367495003 | |
Eosinophilic asthma | contraindication | 367542003 | DOID:9498 |
Primary adrenocortical insufficiency | contraindication | 373662000 | |
Severe diarrhea | contraindication | 409587002 | |
Central nervous system depression | contraindication | 418072004 | |
Acute exacerbation of asthma | contraindication | 708038006 | |
Increased Creatine Phosphokinase | contraindication | ||
Pain in Opioid Naive Patients | contraindication | ||
Opioid Use Within Last 4 Hours in Narcotic-Dependent Patient | contraindication |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 9.31 | acidic |
pKa2 | 7.66 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
90MG;8MG | CONTRAVE | NALPROPION | N200063 | Sept. 10, 2014 | RX | TABLET, EXTENDED RELEASE | ORAL | 7462626 | July 20, 2024 | FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY |
90MG;8MG | CONTRAVE | NALPROPION | N200063 | Sept. 10, 2014 | RX | TABLET, EXTENDED RELEASE | ORAL | 8815889 | July 20, 2024 | FOR EFFECT ON BLOOD GLUCOSE PARAMETERS IN PATIENTS WITH INSULIN RESISTANCE |
100MG;4MG | EMBEDA | ALPHARMA PHARMS | N022321 | Aug. 13, 2009 | DISCN | CAPSULE, EXTENDED RELEASE | ORAL | 8685443 | July 3, 2025 | MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT BY ORALLY ADMINISTERING A PLURALITY OF COMPOSITE SUBUNITS AS CLAIMED |
20MG;0.8MG | EMBEDA | ALPHARMA PHARMS | N022321 | Aug. 13, 2009 | DISCN | CAPSULE, EXTENDED RELEASE | ORAL | 8685443 | July 3, 2025 | MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT BY ORALLY ADMINISTERING A PLURALITY OF COMPOSITE SUBUNITS AS CLAIMED |
30MG;1.2MG | EMBEDA | ALPHARMA PHARMS | N022321 | Aug. 13, 2009 | DISCN | CAPSULE, EXTENDED RELEASE | ORAL | 8685443 | July 3, 2025 | MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT BY ORALLY ADMINISTERING A PLURALITY OF COMPOSITE SUBUNITS AS CLAIMED |
50MG;2MG | EMBEDA | ALPHARMA PHARMS | N022321 | Aug. 13, 2009 | DISCN | CAPSULE, EXTENDED RELEASE | ORAL | 8685443 | July 3, 2025 | MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT BY ORALLY ADMINISTERING A PLURALITY OF COMPOSITE SUBUNITS AS CLAIMED |
60MG;2.4MG | EMBEDA | ALPHARMA PHARMS | N022321 | Aug. 13, 2009 | DISCN | CAPSULE, EXTENDED RELEASE | ORAL | 8685443 | July 3, 2025 | MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT BY ORALLY ADMINISTERING A PLURALITY OF COMPOSITE SUBUNITS AS CLAIMED |
80MG;3.2MG | EMBEDA | ALPHARMA PHARMS | N022321 | Aug. 13, 2009 | DISCN | CAPSULE, EXTENDED RELEASE | ORAL | 8685443 | July 3, 2025 | MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT BY ORALLY ADMINISTERING A PLURALITY OF COMPOSITE SUBUNITS AS CLAIMED |
1.2MG;10MG | TROXYCA ER | PFIZER | N207621 | Aug. 19, 2016 | DISCN | CAPSULE, EXTENDED RELEASE | ORAL | 8685443 | July 3, 2025 | MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT BY ORALLY ADMINISTERING A PLURALITY OF COMPOSITE SUBUNITS AS CLAIMED |
2.4MG;20MG | TROXYCA ER | PFIZER | N207621 | Aug. 19, 2016 | DISCN | CAPSULE, EXTENDED RELEASE | ORAL | 8685443 | July 3, 2025 | MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT BY ORALLY ADMINISTERING A PLURALITY OF COMPOSITE SUBUNITS AS CLAIMED |
3.6MG;30MG | TROXYCA ER | PFIZER | N207621 | Aug. 19, 2016 | DISCN | CAPSULE, EXTENDED RELEASE | ORAL | 8685443 | July 3, 2025 | MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT BY ORALLY ADMINISTERING A PLURALITY OF COMPOSITE SUBUNITS AS CLAIMED |
4.8MG;40MG | TROXYCA ER | PFIZER | N207621 | Aug. 19, 2016 | DISCN | CAPSULE, EXTENDED RELEASE | ORAL | 8685443 | July 3, 2025 | MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT BY ORALLY ADMINISTERING A PLURALITY OF COMPOSITE SUBUNITS AS CLAIMED |
7.2MG;60MG | TROXYCA ER | PFIZER | N207621 | Aug. 19, 2016 | DISCN | CAPSULE, EXTENDED RELEASE | ORAL | 8685443 | July 3, 2025 | MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT BY ORALLY ADMINISTERING A PLURALITY OF COMPOSITE SUBUNITS AS CLAIMED |
9.6MG;80MG | TROXYCA ER | PFIZER | N207621 | Aug. 19, 2016 | DISCN | CAPSULE, EXTENDED RELEASE | ORAL | 8685443 | July 3, 2025 | MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT BY ORALLY ADMINISTERING A PLURALITY OF COMPOSITE SUBUNITS AS CLAIMED |
90MG;8MG | CONTRAVE | NALPROPION | N200063 | Sept. 10, 2014 | RX | TABLET, EXTENDED RELEASE | ORAL | 9107837 | June 4, 2027 | USE OF NALTREXONE AND BUPROPION IN EXTENDED-RELEASE FORM FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY |
100MG;4MG | EMBEDA | ALPHARMA PHARMS | N022321 | Aug. 13, 2009 | DISCN | CAPSULE, EXTENDED RELEASE | ORAL | 7682633 | June 19, 2027 | MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATEMENT BY ORALLY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED. |
100MG;4MG | EMBEDA | ALPHARMA PHARMS | N022321 | Aug. 13, 2009 | DISCN | CAPSULE, EXTENDED RELEASE | ORAL | 8158156 | June 19, 2027 | MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATEMENT BY ORALLY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED. |
20MG;0.8MG | EMBEDA | ALPHARMA PHARMS | N022321 | Aug. 13, 2009 | DISCN | CAPSULE, EXTENDED RELEASE | ORAL | 7682633 | June 19, 2027 | MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATEMENT BY ORALLY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED. |
20MG;0.8MG | EMBEDA | ALPHARMA PHARMS | N022321 | Aug. 13, 2009 | DISCN | CAPSULE, EXTENDED RELEASE | ORAL | 8158156 | June 19, 2027 | MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATEMENT BY ORALLY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED. |
30MG;1.2MG | EMBEDA | ALPHARMA PHARMS | N022321 | Aug. 13, 2009 | DISCN | CAPSULE, EXTENDED RELEASE | ORAL | 7682633 | June 19, 2027 | MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATEMENT BY ORALLY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED. |
30MG;1.2MG | EMBEDA | ALPHARMA PHARMS | N022321 | Aug. 13, 2009 | DISCN | CAPSULE, EXTENDED RELEASE | ORAL | 8158156 | June 19, 2027 | MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATEMENT BY ORALLY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED. |
50MG;2MG | EMBEDA | ALPHARMA PHARMS | N022321 | Aug. 13, 2009 | DISCN | CAPSULE, EXTENDED RELEASE | ORAL | 7682633 | June 19, 2027 | MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATEMENT BY ORALLY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED. |
50MG;2MG | EMBEDA | ALPHARMA PHARMS | N022321 | Aug. 13, 2009 | DISCN | CAPSULE, EXTENDED RELEASE | ORAL | 8158156 | June 19, 2027 | MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATEMENT BY ORALLY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED. |
60MG;2.4MG | EMBEDA | ALPHARMA PHARMS | N022321 | Aug. 13, 2009 | DISCN | CAPSULE, EXTENDED RELEASE | ORAL | 7682633 | June 19, 2027 | MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATEMENT BY ORALLY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED. |
60MG;2.4MG | EMBEDA | ALPHARMA PHARMS | N022321 | Aug. 13, 2009 | DISCN | CAPSULE, EXTENDED RELEASE | ORAL | 8158156 | June 19, 2027 | MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATEMENT BY ORALLY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED. |
80MG;3.2MG | EMBEDA | ALPHARMA PHARMS | N022321 | Aug. 13, 2009 | DISCN | CAPSULE, EXTENDED RELEASE | ORAL | 7682633 | June 19, 2027 | MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATEMENT BY ORALLY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED. |
80MG;3.2MG | EMBEDA | ALPHARMA PHARMS | N022321 | Aug. 13, 2009 | DISCN | CAPSULE, EXTENDED RELEASE | ORAL | 8158156 | June 19, 2027 | MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATEMENT BY ORALLY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED. |
90MG;8MG | CONTRAVE | NALPROPION | N200063 | Sept. 10, 2014 | RX | TABLET, EXTENDED RELEASE | ORAL | 10307376 | Nov. 8, 2027 | USE OF NALTREXONE AND BUPROPION BASED ON AN ESCALATING DOSE SCHEDULE |
90MG;8MG | CONTRAVE | NALPROPION | N200063 | Sept. 10, 2014 | RX | TABLET, EXTENDED RELEASE | ORAL | 8318788 | Nov. 8, 2027 | USE OF NALTREXONE AND BUPROPION IN A LAYERED FORMULATION FOR CHRONIC WEIGHT MANAGEMENT FOR AFFECTING WEIGHT LOSS |
90MG;8MG | CONTRAVE | NALPROPION | N200063 | Sept. 10, 2014 | RX | TABLET, EXTENDED RELEASE | ORAL | 8722085 | Nov. 8, 2027 | USE OF NALTREXONE AND BUPROPION BASED ON AN ESCALATING DOSE SCHEDULE |
90MG;8MG | CONTRAVE | NALPROPION | N200063 | Sept. 10, 2014 | RX | TABLET, EXTENDED RELEASE | ORAL | 9125868 | Nov. 8, 2027 | USE OF NALTREXONE AND BUPROPION BASED ON AN ESCALATING DOSE SCHEDULE |
380MG/VIAL | VIVITROL | ALKERMES | N021897 | April 13, 2006 | RX | FOR SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 7919499 | Oct. 15, 2029 | PREVENTION OF RELAPSE TO OPIOID DEPENDENCE, FOLLOWING OPIOID DETOXIFICATION |
380MG/VIAL | VIVITROL | ALKERMES | N021897 | April 13, 2006 | RX | FOR SUSPENSION, EXTENDED RELEASE | INTRAMUSCULAR | 7919499 | Oct. 15, 2029 | TREATMENT OF ALCOHOL DEPENDENCE |
100MG;4MG | EMBEDA | ALPHARMA PHARMS | N022321 | Aug. 13, 2009 | DISCN | CAPSULE, EXTENDED RELEASE | ORAL | 8623418 | Nov. 7, 2029 | TREATMENT OF MODERATE TO SEVERE CHRONIC PAIN BY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED |
20MG;0.8MG | EMBEDA | ALPHARMA PHARMS | N022321 | Aug. 13, 2009 | DISCN | CAPSULE, EXTENDED RELEASE | ORAL | 8623418 | Nov. 7, 2029 | TREATMENT OF MODERATE TO SEVERE CHRONIC PAIN BY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED |
30MG;1.2MG | EMBEDA | ALPHARMA PHARMS | N022321 | Aug. 13, 2009 | DISCN | CAPSULE, EXTENDED RELEASE | ORAL | 8623418 | Nov. 7, 2029 | TREATMENT OF MODERATE TO SEVERE CHRONIC PAIN BY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED |
50MG;2MG | EMBEDA | ALPHARMA PHARMS | N022321 | Aug. 13, 2009 | DISCN | CAPSULE, EXTENDED RELEASE | ORAL | 8623418 | Nov. 7, 2029 | TREATMENT OF MODERATE TO SEVERE CHRONIC PAIN BY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED |
60MG;2.4MG | EMBEDA | ALPHARMA PHARMS | N022321 | Aug. 13, 2009 | DISCN | CAPSULE, EXTENDED RELEASE | ORAL | 8623418 | Nov. 7, 2029 | TREATMENT OF MODERATE TO SEVERE CHRONIC PAIN BY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED |
80MG;3.2MG | EMBEDA | ALPHARMA PHARMS | N022321 | Aug. 13, 2009 | DISCN | CAPSULE, EXTENDED RELEASE | ORAL | 8623418 | Nov. 7, 2029 | TREATMENT OF MODERATE TO SEVERE CHRONIC PAIN BY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED |
90MG;8MG | CONTRAVE | NALPROPION | N200063 | Sept. 10, 2014 | RX | TABLET, EXTENDED RELEASE | ORAL | 8916195 | Feb. 2, 2030 | USE OF NALTREXONE AND BUPROPION IN EXTENDED-RELEASE FORM FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY |
90MG;8MG | CONTRAVE | NALPROPION | N200063 | Sept. 10, 2014 | RX | TABLET, EXTENDED RELEASE | ORAL | 11033543 | Jan. 10, 2031 | FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY |
90MG;8MG | CONTRAVE | NALPROPION | N200063 | Sept. 10, 2014 | RX | TABLET, EXTENDED RELEASE | ORAL | 9248123 | Jan. 13, 2032 | USE OF NALTREXONE AND BUPROPION FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER |
90MG;8MG | CONTRAVE | NALPROPION | N200063 | Sept. 10, 2014 | RX | TABLET, EXTENDED RELEASE | ORAL | 10403170 | June 5, 2033 | FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY |
90MG;8MG | CONTRAVE | NALPROPION | N200063 | Sept. 10, 2014 | RX | TABLET, EXTENDED RELEASE | ORAL | 11139056 | June 5, 2033 | FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY |
90MG;8MG | CONTRAVE | NALPROPION | N200063 | Sept. 10, 2014 | RX | TABLET, EXTENDED RELEASE | ORAL | 9633575 | June 25, 2033 | FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY |
90MG;8MG | CONTRAVE | NALPROPION | N200063 | Sept. 10, 2014 | RX | TABLET, EXTENDED RELEASE | ORAL | 10231964 | July 2, 2034 | FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY |
90MG;8MG | CONTRAVE | NALPROPION | N200063 | Sept. 10, 2014 | RX | TABLET, EXTENDED RELEASE | ORAL | 10828294 | July 2, 2034 | FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY |
90MG;8MG | CONTRAVE | NALPROPION | N200063 | Sept. 10, 2014 | RX | TABLET, EXTENDED RELEASE | ORAL | 10835527 | July 2, 2034 | FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY |
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Delta-type opioid receptor | GPCR | ANTAGONIST | Ki | 7.99 | WOMBAT-PK | CHEMBL | |||
Kappa-type opioid receptor | GPCR | ANTAGONIST | Ki | 8.93 | WOMBAT-PK | CHEMBL | |||
Mu-type opioid receptor | GPCR | ANTAGONIST | Ki | 9.38 | WOMBAT-PK | CHEMBL | |||
Cytochrome P450 2D6 | Enzyme | IC50 | 6 | DRUG MATRIX | |||||
Neuronal acetylcholine receptor subunit alpha-7 | Ion channel | IC50 | 4.60 | CHEMBL | |||||
Mu-type opioid receptor | GPCR | Ki | 9.34 | CHEMBL | |||||
Mu-type opioid receptor | GPCR | Ki | 9.58 | CHEMBL | |||||
Mu-type opioid receptor | GPCR | Ki | 9.77 | CHEMBL | |||||
Delta-type opioid receptor | GPCR | Ki | 7.91 | CHEMBL | |||||
Delta-type opioid receptor | GPCR | Ki | 8.32 | CHEMBL | |||||
Kappa-type opioid receptor | GPCR | Ki | 9.51 | CHEMBL | |||||
Neuronal acetylcholine receptor subunit alpha-4 | Ion channel | IC50 | 4.51 | CHEMBL | |||||
Kappa-type opioid receptor | GPCR | Ki | 8.97 | CHEMBL | |||||
Kappa-type opioid receptor | GPCR | Ki | 8.84 | CHEMBL | |||||
Opioid receptor | GPCR | Ki | 9.26 | CHEMBL | |||||
Opioid receptors; mu and delta | GPCR | Ki | 9.06 | CHEMBL |
ID | Source |
---|---|
4019853 | VUID |
N0000147939 | NUI |
D02095 | KEGG_DRUG |
16676-29-2 | SECONDARY_CAS_RN |
4018545 | VANDF |
4019853 | VANDF |
C0027360 | UMLSCUI |
CHEBI:7465 | CHEBI |
CHEMBL19019 | ChEMBL_ID |
CHEMBL1201149 | ChEMBL_ID |
D009271 | MESH_DESCRIPTOR_UI |
DB00704 | DRUGBANK_ID |
1639 | IUPHAR_LIGAND_ID |
3368 | INN_ID |
5S6W795CQM | UNII |
5360515 | PUBCHEM_CID |
105069 | RXNORM |
11621 | MMSL |
20600 | MMSL |
5151 | MMSL |
d01406 | MMSL |
001615 | NDDF |
004662 | NDDF |
373546002 | SNOMEDCT_US |
64191009 | SNOMEDCT_US |
87617007 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
NALTREXONE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0406-1170 | TABLET, FILM COATED | 50 mg | ORAL | ANDA | 15 sections |
NALTREXONE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7036 | TABLET, FILM COATED | 50 mg | ORAL | ANDA | 22 sections |
EMBEDA | HUMAN PRESCRIPTION DRUG LABEL | 2 | 16590-897 | CAPSULE, EXTENDED RELEASE | 0.80 mg | ORAL | NDA | 14 sections |
Naltrexone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16729-081 | TABLET, FILM COATED | 50 mg | ORAL | ANDA | 23 sections |
Naltrexone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-632 | TABLET, FILM COATED | 50 mg | ORAL | ANDA | 25 sections |
ContraveExtended-Release | HUMAN PRESCRIPTION DRUG LABEL | 2 | 43063-772 | TABLET, EXTENDED RELEASE | 8 mg | ORAL | NDA | 31 sections |
NALTREXONE HYDROCHLORIDE | Human Prescription Drug Label | 1 | 47335-326 | TABLET, FILM COATED | 50 mg | ORAL | ANDA | 22 sections |
Naltrexone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-2866 | TABLET, FILM COATED | 50 mg | ORAL | ANDA | 27 sections |
ContraveExtended-Release | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50090-2945 | TABLET, EXTENDED RELEASE | 8 mg | ORAL | NDA | 30 sections |
Naltrexone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-3076 | TABLET, FILM COATED | 50 mg | ORAL | ANDA | 28 sections |
NALTREXONE HYDROCHLORIDE | Human Prescription Drug Label | 1 | 50090-3929 | TABLET, FILM COATED | 50 mg | ORAL | ANDA | 23 sections |
Naltrexone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-4925 | TABLET, FILM COATED | 50 mg | ORAL | ANDA | 23 sections |
Naltrexone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51224-206 | TABLET, FILM COATED | 50 mg | ORAL | ANDA | 28 sections |
ContraveExtended-Release | HUMAN PRESCRIPTION DRUG LABEL | 2 | 51267-890 | TABLET, EXTENDED RELEASE | 8 mg | ORAL | NDA | 31 sections |
Naltrexone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53217-261 | TABLET, FILM COATED | 50 mg | ORAL | ANDA | 25 sections |
Naltrexone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-5574 | TABLET, FILM COATED | 50 mg | ORAL | ANDA | 26 sections |
Addex-1000 | HUMAN PRESCRIPTION DRUG LABEL | 1 | 57377-010 | PELLET, IMPLANTABLE | 1000 mg | SUBCUTANEOUS | Export only | 4 sections |
Naltrexone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62135-242 | TABLET, FILM COATED | 50 mg | ORAL | ANDA | 23 sections |
Naltrexone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-1046 | TABLET, FILM COATED | 50 mg | ORAL | ANDA | 27 sections |
Naltrexone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-1047 | TABLET, FILM COATED | 50 mg | ORAL | ANDA | 27 sections |
NALTREXONE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68084-291 | TABLET, FILM COATED | 50 mg | ORAL | ANDA | 16 sections |
Naltrexone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68094-853 | TABLET, FILM COATED | 50 mg | ORAL | ANDA | 26 sections |
Naltrexone | HUMAN PRESCRIPTION DRUG LABEL | 2 | 69364-3143 | IMPLANT | 200 mg | SUBCUTANEOUS | Unapproved drug other | 25 sections |
Naltrexone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70518-1146 | TABLET, FILM COATED | 50 mg | ORAL | ANDA | 23 sections |
NALTREXONE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70518-2718 | TABLET, FILM COATED | 50 mg | ORAL | ANDA | 22 sections |
Naltrexone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71335-0014 | TABLET, FILM COATED | 50 mg | ORAL | ANDA | 23 sections |
NALTREXONE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71335-1480 | TABLET, FILM COATED | 50 mg | ORAL | ANDA | 15 sections |
NALTREXONE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 76519-1160 | TABLET, FILM COATED | 50 mg | ORAL | ANDA | 13 sections |